Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0852W HIGH $0.91
Volume
27.45 M
Value Traded
199.53 K
Short % Float
10.05%
Days to Cover
4.5
-57.94%Week
-75.42%1 Month
-73.26%3 Month
-71.72%6 Month
-95.03%5 Year
-95.03%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.09 M
EPS (TTM)
-0.36
P/E Ratio
-
Ent. Value
3.14 M
Total Shares
35.13 M
Float Shares
19.42 M
Insiders
44.70%
Institutions
1.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
OSRH Catalyst Timeline
Dated clinical, regulatory and corporate events for OSR Holdings, Inc.
Past FDA Catalysts and PDUFA Decisions
How OSRH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every OSRH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VXM01 | recurrent glioblastoma | Phase 2a | 2025-03-26 | objective response rate: 12.0%; partial remission: 12.0%; stable disease: 4.0%; median time to progression: 2.7 months; median os: 11.1 months; overall survival range: 2.2 to 46.5 monthsRead More | Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in GlioblastomaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bellevue Global Life Science Investors LLC10% Owner | BuyWarrant exercise | 430,000 430,000 held | $10.00 | 02/14/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in OSRH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in OSRH for Q2 2026. | ||||
Ownership Trends
OSRH Short Interest
Shares sold short, counted twice a month.
10.05%
Short % of Float
of tradable shares sold short
903.9K
Shares Sold Short
-5.9% vs prior count
4.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
199.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OSRH ranks across every disease it competes in
Competitive Position is a premium feature
See how OSRH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOSRH News
About OSR Holdings, Inc.
Headquarters10900 NE 4TH STREET, SUITE 2300, BELLEVUE, WA, 98004
BIOPHARMAWATCH ELITE PLUS
Trade the next OSRH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime